Phil Rivers Tech Secures Nearly RMB 200 Million in Series A2 Funding to Advance Life World Model-Driven AI4S Platform

Language models give rise to intelligence by representing linguistic logic, physical world models by representing physical laws, and life world models by representing biological mechanisms. Scientific Intelligence (AI4S) is not merely about improving efficiency, but about creating new knowledge and new business paradigms. The life world model is a new tool for humanity to systematically understand the laws of life and decipher disease mechanisms.

In recent years, AI has first demonstrated significant value in R&D stages such as drug molecule generation, substantially improving the efficiency of drug development. However, as AI for Science (AI4S) continues to evolve, industry competition is shifting from an “efficiency race” centered on molecular generation, screening, and optimization toward a “cognitive revolution” focused on understanding disease mechanisms, modeling human biology, and predicting clinical value.

Alongside this trend, enterprises driving source innovation in life sciences through AI4S are increasingly gaining favor from the market and capital.

Exclusive to VCBeat: PHIL RIVERS TECHNOLOGY Co., Ltd (hereinafter referred to as PHIL RIVERS), a leading innovator in AI for Science (AI4S), has secured nearly RMB 200 million in its Series A2 financing. This round of financing was led by Sansure Biotech together with its industrial fund. CASSTAR, an existing shareholder, continued to participate in the investment, with Zhangjiang Sci-Tech Investment and other institutions joining as co-investors.

It is reported that this round of financing will be primarily used for the continuous generation of high-value innovative intellectual property (IP) and global asset layout, as well as the upgrade of the AI4S platform driven by the Life World Model. This includes continuously refining the foundational model matrix—comprising knowledge models, genomic models, signaling pathway models, virtual cell models, and lesion world models—advancing the development of AI agents and experimental validation systems, and accelerating the industrial translation of achievements such as original targets, innovative drug pipelines, and virtual clinical trials, thereby leading source innovation in pharmaceuticals through the full-stack Life World Model platform.

The fundamental challenge facing the industry today lies in the inadequate understanding of disease mechanisms. The true bottleneck in drug development is not “how to create a molecule,” but rather “for which patient population and which disease to develop the drug molecule.”

Guided by this understanding, PHIL RIVERS focuses on “AI for Science (AI4S) + Disease,” building a “Life World Model” platform grounded in digital twins of life functions to realign R&D origins with clinical value. Rather than merely optimizing molecules around known targets, the platform starts from disease mechanisms and clinical needs, employing multi-scale modeling of the genome, signaling pathways, cells, the lesion microenvironment, and patient responses to elucidate disease etiology, identify intervention targets, and define beneficiary populations.

The platform has completed a full-stack upgrade, establishing five foundational model categories: the Biomedical Knowledge Model, the “Population–Individual” Dual-Scale Genomic Language Model, the Signaling Pathway Model, the Virtual Cell Model, and the Lesion World Model. These models respectively handle knowledge comprehension, genetic analysis, pathway map deduction, cellular perturbation prediction, and lesion evolution simulation, collectively constructing a multimodal, temporal panoramic view of disease to achieve dynamic computation of life activities and intervention responses.

From the perspective of PHIL RIVERS, the Life World Model is not a mere extension of the original “human-disease-drug” digital twin system, but rather a dimensional leap from localized digital mapping to full-scale life system modeling. It enables AI to go beyond processing literature, data, and molecules, allowing it to further perceive, understand, and interact with the real-world entity of human life.

Building on this foundation, PHIL RIVERS directs its technological capabilities toward two of the most challenging and industrially valuable “holy grail” problems in drug development: target discovery and clinical trials. The former requires identifying targets with genuine causal relationships and clinical value from complex disease mechanisms, while the latter involves determining indications, beneficiary populations, and potential efficacy before drugs enter large-scale clinical validation.

To achieve the aforementioned objectives, the key lies in transforming fragmented life science information into computational and inferential systemic capabilities. The Life World Model is the systematic and engineering-oriented embodiment of this scientific paradigm. It organizes life-related data—originally scattered across literature, multi-omics, cellular experiments, pathological studies, and clinical records—into a digital foundation that can be continuously accessed and reasoned by AI, thereby providing more comprehensive underlying support for AI-driven life science research and innovative drug development.

The value ceiling of the life sciences, healthcare, pharmaceutical, and health industries is determined by the depth of our understanding of diseases. An innovative drug pipeline can be valued at tens of billions of dollars, a key therapeutic target at hundreds of billions, while systematic research into any major disease can unlock long-term value in the trillions. Value amplifies progressively from pipelines to targets, and further to diseases, making disease cognition the core asset driving source innovation in pharmaceuticals. PHIL RIVERS stands at the apex of this three-tiered value pyramid, leveraging AI-driven accumulation of disease understanding to set this flywheel in motion.

PHIL RIVERS leverages its Life World Model as the foundational infrastructure to continuously accumulate disease-related data, distill insights, and create high-value intellectual property (IP), thereby establishing a complete closed-loop system encompassing “disease research – insight generation – asset commercialization – data feedback – intelligent enhancement.” This framework serves not merely as an R&D tool for individual projects, but as a high-value IP factory capable of consistently producing original therapeutic targets and innovative pipelines. As understanding of diseases deepens, both the scientific and commercial value of PHIL RIVERS continue to expand.

Leveraging the engineering capabilities of its AI4S platform, the company is accelerating commercial implementation and delivering two solutions to the industry: D2P (Disease to Product) and T2I (Target to Indication). The T2I solution adopts a deep empowerment model, utilizing digital twins to simulate clinical trials, helping clients precisely identify indications and patient profiles to guide pipeline decision-making. The D2P solution follows a value co-creation model, starting from the origin of the disease to collaborate with pharmaceutical companies on joint R&D, jointly identifying core targets, covering the full lifecycle from target to product, building high-barrier pipelines, and establishing a leading position in the sector.

Currently, this pathway—driven by disease understanding to fuel scientific discovery and asset translation—is being continuously validated through real-world pipelines and clinical studies. PHIL RIVERS’ self-developed Class I novel drug, PR00012, has entered Phase I clinical trials with smooth progress, while multiple other pipeline candidates are also advancing. Furthermore, PHIL RIVERS has established in-depth collaborations with several national medical centers, conducting mechanistic research and exploring original targets for major diseases such as cancer and psychiatric disorders, achieving phased results. With platform capabilities being implemented and pipelines progressing, PHIL RIVERS is steadily turning its overarching strategic vision into reality.

PHIL RIVERS’ AI4S platform combines foundational originality with boundless potential for the life sciences, healthcare, pharmaceutical, and health industries, earning joint recognition from industrial capital, hard-tech investors, and regional innovation forces.

Currently, PHIL RIVERS’ AI4S platform, centered on its Life World Model, is being deeply integrated into industrial practice, continuously yielding high-value innovations and their commercial applications. In the future, this technological paradigm is poised to break through the boundaries of human understanding of life, unleashing trillion-dollar transformations in the life and health sectors. More people worldwide will gain access to high-quality, affordable healthcare services, creating infinite possibilities for expanding the frontiers of human health and enabling humanity to evolve into a trans-century species.